MIBio 2022: Stability of biopharmaceuticals - From molecular interactions to successful products

Synopsis

Following a 2-year break due to the pandemic, we are delighted to announce the return of the MIBio in-person conference. As an added celebration, this will be the 10th meeting of the MIBio conference series!

The MIBio conference series engages leading experts from industry and academia in a discussion on how the latest molecular interaction-based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly, and safer therapeutic products.

To tackle the Covid pandemic, the last two years have brought about considerable changes in the biopharmaceutical formulation landscape. The critical importance of the storage and shipment stability and ensuring the reliability of the supply chain of the key formulation components were brought to the attention of the entire world as we watched the phenomenally rapid and efficient development of the leading Covid vaccines. Significant advances have also been made in new formulation approaches to ensure not only stability and safety but also the efficacy of state-of-the-art therapeutic modalities such as mRNA and viral vector products.

Attendees

MIBio 2022 will focus on discussing all of these challenges and technological advances, particularly focusing on molecular interactions, formulation, regulatory landscape, and drug product development.

We expect more than 100 delegates from industry and academia to create a stimulating event fostering new collaborations and discoveries that will help steer the development of the next generation formulation technologies. We will be inviting abstracts for poster submissions and welcome applications for sponsor and exhibitor slots for the day.

Programme

The programme will be confirmed shortly and can be found here.

Venue and Contact

Fees